Our valuation is heavily driven by key drugs Vimpat, Cimzia, and Briviact. For these drugs, we model revenue declines due to generic competition in 2022, 2024, and 2026, respectively.

The primary endpoint for the phase 2A trial was the least squares mean change in Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) from baseline to 12 weeks of treatment ...

UCB shares, which had fallen 28 percent in the year on fears that Cimzia's approval might be delayed, shot up as much as 29.6 percent on Wednesday.

Alvotech, a global biotech firm, has successfully completed its acquisition of Xbrane Biopharma's research and development organization and a biosimilar candidate for Cimzia® (certolizumab pegol ...

Europe's drug watchdog has recommended EU approval of UCB SA's <UCB.BR> Cimzia drug as a treatment for rheumatoid arthritis, the Belgian company said on Friday, clearing the way for it to be ...